Ian C. Read (born 1953) is a Scottish-born American businessman, a chartered accountant, and since 2010 the chief executive officer (CEO) of Pfizer, the world's largest drug company.
Early life
Read was born in Forfar, Scotland, to a Scottish mother, but his parents returned to Rhodesia羅德西亞 (now Zimbabwe 金巴布文威) when he was six-weeks-old, and he grew up there.
Read received a bachelor's degree in Chemical Engineering from Imperial College London in 1974. He qualified as a chartered accountant in 1978. Career
Read
has spent his entire career with Pfizer, starting in 1978 as an
operational auditor. He worked in Latin America through 1995, holding
positions ranging from CFO of Pfizer Mexico (Pfizer's largest subsidiary
in Latin America) to country manager of Brazil. In 1996, he was
appointed president of the Pfizer International Pharmaceuticals Group,
Latin America/Canada. He assumed the position of executive vice
president—Europe/Canada in May 2000, added the responsibilities for
Africa/Middle East region as of January 2004 and responsibilities for
Latin America in March 2006. He was named vice president of Pfizer in
2001 and promoted to president of worldwide pharmaceutical operations in
2006. He is a member of the Pfizer Leadership Team.[6]
On 5
December 2010, When Read "took over from Jeffrey Kindler as Pfizer’s
CEO, the drug firm–the world’s largest–was facing the impending patent
expiration of Lipitor, the bestselling drug ever made, and the utter
failure of one of the most lavishly funded research laboratories on the
planet to develop much of anything." Read is also a director of
Kimberly-Clark. Read is now an American citizen.
By October
2015 during the Drug Pricing Firestorm, Forbes journalist Matthew
Herper, wrote how "Read, with his calculating mind, must get through the
public’s rage over six-figure price tags for breakthrough drugs and yet
keep Pfizer’s pricing power more or less intact. Doing so is absolutely
critical: 34% of Pfizer’s revenue growth over the past three years has
come from increasing prices on existing drugs, according to SSR, a
Stamford, Conn.-based consulting firm. New medicines, especially for
cancer, are selling for $100,000-plus–prices that were unimaginable five years ago."
Personal life Read has a holiday home near Bonita Springs, Florida.